SOHO State of the Art Updates and Next Questions |The Role of Maintenance Therapy in Acute Myeloid Leukemia

被引：5

作者：

Babakhanlou, Rodrick ^{[1
,2
]}

Ravandi-Kashani, Farhad ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd Houston, Maryland, TX 77030 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷 / 01期

关键词：

Lymphoma; Myeloma Leukemia; 23; 1; rights FLT3 kinase inhibitors; Hypomethylating agents; Immunotherapy; Measurable residual disease; Maintenance therapy; ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC-CELL TRANSPLANTATION; INTERNAL TANDEM DUPLICATION; NATURAL-KILLER-CELLS; REGULATORY T-CELLS; RECOMBINANT INTERLEUKIN-2; POSTREMISSION THERAPY; REMISSION INDUCTION; 1ST REMISSION; RELAPSED AML;

D O I：

10.1016/j.clml.2022.11.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acute myeloid leukemia (AML) is an aggressive disease predominantly affecting the elderly population. Although, up to 65% of patients with AML achieve a complete remission with standard induction chemotherapy, the majority of patients will relapse and succumb to the disease. Although maintenance therapy is a component of standard management for various hematological malignancies, such as acute lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL) or multiple myeloma, past studies investigating the role of maintenance therapy in AML were unable to demonstrate an advantage in overall survival, and therefore, it has not been an established practice in the treatment of AML. For patients, who are not candidates for stem cell transplant, effective AML maintenance therapies are needed in order to reduce the risk of relapse. Over the past decades, many investigators have examined the role of various maintenance strategies in AML; with the intention to prolong remission and overall survival. This review will provide an overview of prior and ongoing approaches and strategies to maintenance therapy for AML.

引用

页码：1 / 7

页数：7

共 91 条

[31] Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study [J].

Foran, James M. ;

Sun, Zhuoxin ;

Claxton, David F. ;

Lazarus, Hillard M. ;

Arber, Daniel A. ;

Rowe, Jacob M. ;

Paietta, Elisabeth ;

Racevskis, Janis ;

Altman, Jessica K. ;

Luger, Selina M. ;

Al-Kali, Aref ;

Zheng, Hong ;

Pratz, Keith W. ;

Broun, Edward R. ;

Powell, Bayard L. ;

O'Dwyer, Kristen Marie ;

Godwin, John E. ;

Ofran, Yishai ;

Litzow, Mark ;

Tallman, Martin S. .

BLOOD, 2019, 134

[32] Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial [J].

Gao, Lei ;

Zhang, Yanqi ;

Wang, Sanbin ;

Kong, Peiyan ;

Su, Yi ;

Hu, Jiong ;

Jiang, Ming ;

Bai, Hai ;

Lang, Tao ;

Wang, Jishi ;

Liu, Li ;

Yang, Tonghua ;

Huang, Xiaobing ;

Liu, Fang ;

Lou, Shifeng ;

Liu, Yao ;

Zhang, Cheng ;

Liu, Hong ;

Gao, Li ;

Liu, Jia ;

Zhu, Lidan ;

Wen, Qin ;

Chen, Ting ;

Wang, Ping ;

Rao, Jun ;

Mao, Min ;

Wang, Cunbang ;

Duan, Xianlin ;

Luo, Le ;

Peng, Xiangui ;

Cassady, Kaniel ;

Zhong, Jiang F. ;

Zhang, Xi .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (36) :4249-+

[33] Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial [J].

Goldstone, AH ;

Burnett, AK ;

Wheatley, K ;

Smith, AG ;

Hutchinson, RM ;

Clark, RE .

BLOOD, 2001, 98 (05) :1302-1311

[34] Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) [J].

Goodyear, Oliver C. ;

Dennis, Mike ;

Jilani, Nadira Y. ;

Loke, Justin ;

Siddique, Shamyla ;

Ryan, Gordon ;

Nunnick, Jane ;

Khanum, Rahela ;

Raghavan, Manoj ;

Cook, Mark ;

Snowden, John A. ;

Griffiths, Mike ;

Russell, Nigel ;

Yin, John ;

Crawley, Charles ;

Cook, Gordon ;

Vyas, Paresh ;

Moss, Paul ;

Malladi, Ram ;

Craddock, Charles F. .

BLOOD, 2012, 119 (14) :3361-3369

[35] Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes [J].

Griffin, James D. ;

Song, Yan ;

Yang, Hongbo ;

Freimark, Jonathan ;

Shah, Manasee, V .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (05) :553-565

[36] ACTIVE IMMUNOTHERAPY IN ACUTE MYELOGENOUS LEUKEMIA AND INDUCTION OF 2ND AND SUBSEQUENT REMISSIONS [J].

HARRIS, R ;

ZUHRIE, SR ;

FREEMAN, CB ;

TAYLOR, GM ;

MACIVER, JE ;

GEARY, CG ;

DELAMORE, IW ;

HULL, PJ ;

TOOTH, JA .

BRITISH JOURNAL OF CANCER, 1978, 37 (02) :282-288

[37] Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients [J].

Huls, Gerwin ;

Chitu, Dana A. ;

Havelange, Violaine ;

Jongen-Lavrencic, Mojca ;

van de Loosdrecht, Arjan A. ;

Biemond, Bart J. ;

Sinnige, Harm ;

Hodossy, Beata ;

Graux, Carlos ;

Kooy, Rien van Marwijk ;

de Weerdt, Okke ;

Breems, Dimitri ;

Klein, Saskia ;

Kuball, Jurgen ;

Deeren, Dries ;

Terpstra, Wim ;

Vekemans, Marie-Christiane ;

Ossenkoppele, Gert J. ;

Vellenga, Edo ;

Lowenberg, Bob ;

Breems, D. A. ;

Verhoef, G. ;

Schuermans, C. ;

Terpstra, J. ;

Van Esser, J. W. J. ;

van Lammeren-Venema, D. ;

Legdeur, M. C. J. C. ;

Jie, G. K. S. ;

van der Velden, W. ;

Lowenberg, B. .

BLOOD, 2019, 133 (13) :1457-1464

[38] Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial [J].

Hunault-Berger, M. ;

Maillard, N. ;

Himberlin, C. ;

Recher, C. ;

Schmidt-Tanguy, A. ;

Choufi, B. ;

Bonmati, C. ;

Carre, M. ;

Couturier, M-A ;

Daguindau, E. ;

Marolleau, J-P ;

Orsini-Piocelle, F. ;

Delaunay, J. ;

Tavernier, E. ;

Lissandre, S. ;

Ojeda-Uribe, M. ;

Sanhes, L. ;

Sutton, L. ;

Banos, A. ;

Fornecker, L. M. ;

Bernard, M. ;

Bouscary, D. ;

Saad, A. ;

Puyade, M. ;

Rouille, V. ;

Luquet, I. ;

Bene, M. C. ;

Hamel, J-F ;

Dreyfus, F. ;

Ifrah, N. ;

Pigneux, A. .

BLOOD CANCER JOURNAL, 2017, 7 :e568-e568

[39] INTENSIVE MAINTENANCE TREATMENT IN ACUTE MYELOGENOUS LEUKEMIA (AML) - SINGLE INSTITUTION EXPERIENCE OF A MULTICENTER RANDOMIZED TRIAL [J].

JEHN, U ;

KNUPPEL, W ;

WILMANNS, W .

ONKOLOGIE, 1988, 11 (01) :13-17

[40] LONG-TERM OUTCOME OF POSTREMISSION CHEMOTHERAPY FOR ADULTS WITH ACUTE MYELOID-LEUKEMIA USING DIFFERENT DOSE-INTENSITIES [J].

JEHN, U .

LEUKEMIA & LYMPHOMA, 1994, 15 (1-2) :99-112

← 1 2 3 4 5 6 7 8 9 10 →